Company Encyclopedia
View More
name
Journey Medical
DERM.US
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc.
4.513 T
DERM.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking82/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-47.05%E
    • Profit Margin-14.58%D
    • Gross Margin67.36%A
  • Growth ScoreB
    • Revenue YoY2.82%C
    • Net Profit YoY52.75%B
    • Total Assets YoY33.02%A
    • Net Assets YoY137.03%A
  • Cash ScoreD
    • Cash Flow Margin-685.66%E
    • OCF YoY2.82%C
  • Operating ScoreB
    • Turnover0.8B
  • Debt ScoreD
    • Gearing Ratio69.60%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FY2025 EPS Forecast for Journey Medical Decreased by Analyst

    HC Wainwright has decreased its FY2025 EPS forecast for Journey Medical to ($0.53) from ($0.45), maintaining a "Buy" rating with a $13.00 target price. The stock has mixed ratings from analysts, with a consensus "Hold" rating and an average target price of $12.17. Journey Medical's recent quarterly earnings missed estimates, and the stock opened at $7.89 on NASDAQ. Institutional investors have been adjusting their positions in the company.

    Market Beat·
    US
    DERM
    +2.18%
    Market Beat·
    US
    DERM
    +2.18%

    B. Riley Increases Earnings Estimates for Journey Medical

    B. Riley analysts have increased their FY2029 EPS estimates for Journey Medical to $0.93 from $0.85. The stock has a consensus rating of 'Hold' with an average price target of $12.17. Journey Medical's stock is currently trading at $7.48, down 2.7%. The company reported a Q3 loss of $0.09 per share, missing estimates by $0.01. Institutional investors have been adjusting their positions in the stock.

    Market Beat·
    US
    DERM
    +2.18%
    Market Beat·
    US
    DERM
    +2.18%

    Journey Medical Corporation Reports Strong Q3 2025 Growth

    Journey Medical Corporation reported strong Q3 2025 growth with net revenues of $17.6 million, a 21% increase from the previous year. Emrosi™ drove growth with a 146% rise in prescriptions, generating $4.9 million in sales. Gross margin was 67.4%, and net loss improved to $2.3 million. Adjusted EBITDA rose to $1.7 million. Cash reserves increased to $24.9 million. The company is optimistic about Emrosi's continued growth and its strategic initiatives in the dermatology market.

    Tip Ranks·
    US
    DERM
    +2.18%
    Tip Ranks·
    US
    DERM
    +2.18%

    Journey Medical’s Earnings Call Highlights Growth and Challenges

    Journey Medical Corporation's Q3 earnings call highlighted a 21% year-over-year revenue growth, driven by the successful launch of Amrozi. Despite challenges from declining legacy product revenues and reliance on co-pay assistance programs, the company is addressing these issues strategically. Amrozi's market acceptance and positive physician feedback have been strong. Financial metrics improved, with EBITDA losses reduced and positive adjusted EBITDA achieved. The company remains optimistic about sustainable EBITDA positivity by Q4 2025, with plans to expand market coverage further.

    Tip Ranks·
    US
    DERM
    +2.18%
    Tip Ranks·
    US
    DERM
    +2.18%

    Journey Medical | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 17.63 M

    LB filings·
    US
    DERM
    +2.18%
    LB filings·
    US
    DERM
    +2.18%
    © 2025 Longbridge｜Disclaimer